Please check your internet connection and try again.
# Walethmade bromide
## Overview
Walethmade bromide is a synthetic opioid analgesic.
## Primary Indications
* Management of moderate to severe pain.
## Adult Dosing
* **Oral:** The dose is highly individualized based on pain severity, prior opioid exposure, and patient response. Titration is crucial. Usual starting doses range from 5 mg to 20 mg every 4-6 hours as needed.
* **Intravenous:** Typically administered in a hospital setting for acute pain. Doses vary widely, often starting at 1-5 mg IV, titrated to effect.
*Maximum doses are not well-established and depend on individual patient needs and tolerance. Dosing should be guided by pain assessment.*
## Pediatric Dosing
* Dosing in pediatric populations is not well-established and should be approached with extreme caution. Refer to specific pediatric guidelines or consult a pediatric pain specialist.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary, especially in severe impairment. Monitor closely for signs of toxicity.
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, especially in severe impairment. Monitor closely for signs of toxicity.
* **Elderly:** May be more sensitive to the effects; consider starting with lower doses and titrating slowly.
## Contraindications
* Known hypersensitivity to walethmade bromide or other opioids.
* Significant respiratory depression.
* Acute or severe bronchial asthma or hypercapnia.
* Concurrent use with MAO inhibitors or within 14 days of their discontinuation.
* Gastrointestinal obstruction, including paralytic ileus.
## Adverse Effects
Common: Constipation, nausea, vomiting, somnolence, dizziness, pruritus, headache.
Serious: Respiratory depression, opioid-induced hyperalgesia, neonatal withdrawal syndrome, severe hypotension, seizure.
## Key Drug Interactions
* **CNS Depressants (e.g., benzodiazepines, alcohol, sedatives, hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Potentially life-threatening reactions, including respiratory depression, cardiovascular collapse, and seizures.
* **CYP3A4 Inhibitors (e.g., azole antifungals, macrolide antibiotics, protease inhibitors):** May increase walethmade bromide plasma concentrations, leading to increased adverse effects.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease walethmade bromide plasma concentrations, leading to reduced efficacy.
## Monitoring
* Pain assessment regularly.
* Respiratory rate, depth, and oxygen saturation.
* Level of consciousness and sedation.
* Bowel function.
* Signs and symptoms of opioid withdrawal.
## Clinical Pearls
* Walethmade bromide has a risk of abuse, addiction, and misuse, which can lead to overdose and death. Prescribe and dispense with caution.
* Initiate treatment at the lowest effective dose and titrate upwards based on patient response and tolerance.
* Advise patients about the risks of driving or operating heavy machinery while taking this medication.
* Consider co-prescribing a laxative to prevent or manage opioid-induced constipation.
* Ensure naloxone is readily available for emergency reversal of opioid overdose.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing recommendations may vary based on individual patient factors and local protocols.*
